Status: Recruiting
UKK-0018 as an Immunotherapeutic for Treatment of Peanut Allergies
This study will test a new investigational treatment called UKK-0018. UKK-0018 as an immunotherapeutic for the treatment of peanut allergies. The treatment is given by injection and is designed to train the immune system to tolerate peanut exposure over time.
Participants needed: 40
Trial details
Phase: Phase 1, Phase 2Age: 18-55Biological sex: AllType: InterventionalSponsor: Ukko IncUpdated: Jun 25, 2026Locations: 5
Eligibility criteria
Adults 18-55 years old [+5]
asthma based on NHLBI [+9]